Anti-SARS-CoV-2 REGN-COV2

Anti-SARS-COV-2 REGN-COV2 is a combination of novel antibodies designed by Regeneron for both the prevention and treatment of SARS-COV-2, the virus that causes COVID-19. This drug is a combination of the antibodies REGN10933 and REGN10987, derived from humanized VelocImmune® mice in addition to blood samples from patients who have recovered from COVID-19. These antibodies have been formulated to bind to multiple locations on the SARS-COV-2 spike protein, preventing viral escape. Two upcoming publications in the journal, Science, will provide additional information about preclinical research with the Anti-SARS-COV-2 REGN-COV2 antibody cocktail.

Clinical trials for this drug started on June 11, 2020. Regeneron's clinical trial will study the effects of this drug on hospitalized COVID-19 patients, symptomatic COVID-19 patients (non-hospitalized), and uninfected individuals at high-risk of infection, including contacts of an infected individual.